The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...
Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...
On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...
Adtran today launched the industry's first full C-band tunable 50Gbit/s SFP56 DWDM PAM4 pluggable transceiver. The AccessWave50tm is specifically designed to help mobile network operators expand 5G ...
Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative therapies for prevention and treatment of breast cancers, announces the filing of a new provisional patent ...
Fresenius said the U.S. Food and Drug Administration has approved a biologics license application for its operating company's bone-disease drugs. The approval concerns Fresenius Kabi's Conexxence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback